SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the "Company") (NASDAQ:AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview and participate in one-on-one meetings at the Baird Global Healthcare Conference and the Morgan Stanley 21st Annual Global Healthcare Conference, both being held in New York, NY. The presentations will focus on the status of Ambrx's lead clinical candidates, ARX788 and ARX517.
Presentation details are below:
Baird Global Healthcare Conference:
Date: Tuesday, September 12, 2023
Time: 10:50 AM ET
Morgan Stanley 21st Annual Global Healthcare Conference:
Date: Wednesday, September 13, 2023
Time: 4:15 PM ET
About Ambrx Biopharma Inc.
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple ...